ClinicalTrials.gg
RecruitingNCT05563363Updated Aug 28, 2025

Home Treatment for Individuals Suffering From Severe Addictive Disorders

An interventional study of Hospital-like treatment in patients' home and standard inpatient treatment in Substance Use Disorders, sponsored by Louise Penzenstadler. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-28.

Sponsored by Louise Penzenstadler · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Dec 2022; still recruiting 3 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Substance-Related Disorders with a site in Switzerland — 6 open to participants now, 7 under way, none of them phase 3. Substance-Related Disorders · Switzerland.

Planned enrollment
10th of 23
40 · median 28
Started
2022
the only one that year
No phase
14 of 27
6 open now
Registered
22nd of 27
by date
Lead sponsor
2 of 27
Louise Penzenstadler

Among the 27 studies in Substance-Related Disorders with a site in Switzerland, this one is the 10th largest by planned enrollment of the 23 interventional ones that give a count, is the only one that started in 2022, is one of 14 with no phase, and was the 22nd registered.

Substance-Related Disorders

2,242 studies on the registry are indexed under Substance-Related Disorders; 408 are open to participants now.

Browse Substance-Related Disorders studies →

Open to participants now

6 of the 27 studies in Substance-Related Disorders with a site in Switzerland are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 266 Substance-Related Disorders studies recruiting now, 130 (49%) set no upper age limit and 117 (44%) stop at 75 or younger; 55 take children under 18; 90 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Substance-Related Disorders with a site in Switzerland, or all of them as a file.
02

Study summary

Home Treatment (HT) has been successfully implemented in adult psychiatry in several countries including Switzerland. Patients with addiction problems were generally excluded even if the latter was not the main diagnosis. On the other hand, community treatments have successfully been established for these individuals. The investigators have recently offered HT to persons with severe addictive disorders which was well accepted.

The investigators intend to conduct a pilot study to prepare a large-scale study if successful. The investigators intend to compare HT to treatment as usual (regular inpatient treatment) on a specialized ward with respect to readmission rates during 6 months after discharge. The data show that 70.8% of all readmissions occur during the first 6 months. Therefore, a period of 6 months is considered an adequate time interval to sufficiently answer this pilot study's question.

03

Conditions studied

  • Substance Use Disorders
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Substance use disorder
  • age 18 or above
  • sufficient french language skills
  • competent subjects
  • consent to randomization progress

Exclusion criteria

Exclusion Criteria:

  • organic brain disease or developmental disorder
  • non voluntary admission
  • severe somatic comorbidity
  • History of complicated substance withdrawal
  • acute suicidal ideation
  • aggressive behavior
  • acute psychiatric disease such as mania or psychosis
  • distance to center (must be reachable within 60 minutes)
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Home treatment

    Home visits by care staff at the same frequency as in hospital

    Other: Hospital-like treatment in patients' home

  • Active comparator
    Standard inpatient treatment

    Inpatient treatment on hospital ward

    Other: standard inpatient treatment

Interventions

  • OtherHospital-like treatment in patients' home

    Hospital-like treatment in patients' home. Caregivers, medical doctors and social workers will make several visits per day to the patients' home. 24/7 contact is available.

  • Otherstandard inpatient treatment

    Inpatient treatment on addiction ward

06

What researchers measure

Primary outcomes

  1. readmission rates

    Number of readmissions to hospital during the 6 months following discharge

    Time frame: 6 month post-discharge

Secondary outcomes

  1. time to readmission

    Number of days between discharge and readmission during the 6 months following discharge

    Time frame: 6 months

  2. length of hospitalization

    total number of days spent in hospital during the 6 months following discharge

    Time frame: 6 months

  3. number of emergency room visits

    number of emergency room visits during the 6 months following discharge

    Time frame: 6 months

  4. clinical outcome

    clinical outcomes measured with Health of the Nation Outcome scale (HoNOS) scoring 0 (no symptoms) to 48 (high symptom level) and the Brief Symptom Check-List (short form of the Brief Symptom Inventory), scoring 0-53 items (higher score = more symptoms). Measured at the start and end of intervention/hospital treatment.

    Time frame: 6 months

  5. patient satisfaction

    Patient satisfaction measured with the S-ANQ (https://www.anq.ch/en/), a questionnaire used by all Swiss hospitals to measure patient satisfaction with treatment. The questionnaire includes 6 questions which are marked from 0 not at all satisfied to 5 = very satisfied. Scoring 0 (not at all satisfied) to 30 (very satisfied)

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2022 (actual). Primary completion is estimated for Dec 2025, 36 months after the start.

Of 819 non-industry interventional studies with no phase under Substance-Related Disorders, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 53. This study's planned 36 months is close to that.

Counting every sponsor, half of 859 studies reached it within 34 months; a quarter within 17 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2022
First posted
Oct 3, 2022
StartActual
Dec 1, 2022
Primary completionEst.
Dec 31, 2025
CompletionEst.
May 31, 2026
Last update
Aug 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05563363
Lead sponsor
Louise Penzenstadler
Responsible party
Louise Penzenstadler (Dr, University Hospital, Geneva) — Sponsor-investigator
First posted
Oct 3, 2022
Start date
Dec 1, 2022
Primary completion
Dec 31, 2025 (estimated)
Completion
May 31, 2026 (estimated)
Last update
Aug 28, 2025

Study contacts

Louise Penzenstadler, MD
Contact
Louise.E.Penzenstadler@hcuge.ch
+41223725750

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion